STOCK TITAN
  1. Home
  2. Sec-filings
  3. OKYO
  4. [Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership

[Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

OKYO Pharma Ltd director John P. Brancaccio has filed an initial ownership report showing his equity position in the company. He directly holds 30,201 shares of common stock, plus multiple option awards over OKYO common shares with exercise prices between $1.46 and $2.13 per share and expirations ranging from 2033 to 2035. These options vest in staggered annual tranches from 2024 through 2029, giving him long‑term, option-based exposure in addition to his current shareholdings.

Positive

  • None.

Negative

  • None.
Insider BRANCACCIO JOHN P
Role null
Type Security Shares Price Value
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding COMMON STOCK -- -- --
Holdings After Transaction: Options — 3,847 shares (Direct, null); COMMON STOCK — 30,201 shares (Direct, null)
Footnotes (1)
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
BRANCACCIO JOHN P
(Last)(First)(Middle)
C/O OKYO PHARMA LTD,
14-15 CONDUIT STREET
(Street)
LONDONW1S 2XJ
(City)(State)(Zip)
UNITED KINGDOM
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK30,201D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options03/14/202403/14/2033common stock3,847$2.13D
Options03/14/202503/14/2033common stock3,846$2.13D
Options03/14/202603/14/2033common stock3,846$2.13D
Options03/14/202703/14/2033common stock3,846$2.13D
Options11/24/202411/24/2033common stock5,000$1.65D
Options11/24/202511/24/2033common stock5,000$1.65D
Options11/24/202611/24/2033common stock5,000$1.65D
Options11/24/202711/24/2033common stock5,000$1.65D
Options03/13/202503/13/2034common stock13,333$1.46D
Options03/13/202603/13/2034common stock13,334$1.46D
Options03/13/202703/13/2034common stock13,333$1.46D
Options01/29/202501/29/2035common stock839$1.6D
Options01/29/202601/29/2035common stock120$1.6D
Options01/29/202701/29/2035common stock120$1.6D
Options01/29/202801/29/2035common stock121$1.6D
Options01/29/202601/29/2035common stock1,327$1.6D
Options01/29/202701/29/2035common stock1,327$1.6D
Options01/29/202801/29/2035common stock1,327$1.6D
Options01/29/202901/29/2035common stock1,328$1.6D
Options03/25/202603/25/2035common stock12,500$1.5D
Options03/25/202703/25/2035common stock12,500$1.5D
Options03/25/202803/25/2035common stock12,500$1.5D
Options03/25/202903/25/2035common stock12,500$1.5D
Explanation of Responses:
/s/ John Brancaccio06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR